A Phase 4 interventional study of Mitomycin in Bladder Cancer, sponsored by Azienda Ospedaliera "Sant'Andrea". Status unknown. Open to male participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-31.
Sponsored by Azienda Ospedaliera "Sant'Andrea" · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing mitomycin in Urinary Bladder Neoplasms — 5 open to participants now, 10 under way, 2 of them phase 3. Mitomycin · Urinary Bladder Neoplasms.
Among the 26 studies testing mitomycin in Urinary Bladder Neoplasms, this one is the 5th largest by planned enrollment, is the only one that started in 2019, is one of 2 in phase 4, and was the 15th registered.
1,803 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.
Browse Urinary Bladder Neoplasms studies →5 of the 26 studies testing mitomycin in Urinary Bladder Neoplasms are open now, in 4 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
National Cancer Center, Korea · Sites in Korea, Republic of
Ages 20+
Hospital Centre Biel/Bienne · Sites in Switzerland
Ages 18+
First Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Mitomycin: first FDA approval 1981 (MUTAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.
This study: 30 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 14 · Phase 3 8 · Phase 4 2
First in 2001; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 60 across 1,299 interventional studies indexed under Urinary Bladder Neoplasms.
Median enrollment 61 across the 26 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
Azienda Ospedaliera "Sant'Andrea" is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Azienda Ospedaliera "Sant'Andrea" has 1 study filed under Urinary Bladder Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies testing mitomycin in Urinary Bladder Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05024734Roland Seiler-BlarerGuiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids | 2026-12-31 |
| NCT07821177Dana-Farber Cancer InstituteBladder Preservation or Cystectomy for MIBC | 2027-09 |
| NCT07189793First Affiliated Hospital of Wenzhou Medical UniversityToripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies testing mitomycin in Urinary Bladder Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A consecutive series of patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled in several centres. The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after Trans-Urethral Resection of the Bladder (TURB) and re-TURB prior to randomization and only subjects who fulfil the inclusion criteria will be included. Patients selected for the study, are centrally randomized (randomization is performed at the Sant'Andrea Hospital) to receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with Immucyst (81 mg Connaught strain BCG). Patients in group two received BCG treatment with the same protocol with a 40 mg mitomycin instillation the day before .
Methods:
A consecutive series of patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled in several centres
Clinical evaluation:
Patients with High Risk Non-Muscle Invasive Bladder Cancer will be enrolled. For each patients we evaluate the following parameters:
Urinary symptoms evaluation:
Laboratories Analyses
Endoscopic bladder evaluation (video-recorded and centrally evaluated)
Follow-up
Intervention:
The subjects will be assessed for eligibility at the screening visit (Visit 1) three weeks after TURB and re-TURB prior to randomization and only subjects who fulfil the inclusion criteria will be included: patients with a diagnosis of High risk Non Muscle Invasive Bladder Cancer (NMIBC): T1 tumor, G3, Carcinoma in Situ (CIS), or multiple and recurrent and large (>3 cm) Ta or patients in the last EAU recurrence category (EAU/EORTC recurrence score >/=10). Patients selected for the study, are centrally randomized (randomization is performed at the Sant'Andrea Hospital) to receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with Immucyst (81 mg Connaught strain BCG). Patients in group two received BCG treatment with the same protocol with a 40 mg mitomycin instillation the day before .
Adverse Events All the adverse events that will occur in the study will be recorded in the case report form (CRF).
An adverse event (AE) is defined as a harmful clinical event occurring in a patient or a human volunteer involved in a clinical experimentation who received a drug that does not necessarily have a relationship with the treatment given. It is considered AE any medical occurrence including undesirable signs or symptoms or abnormal lab finding.
A Serious Adverse Event (SAE) is an AE that, independently from the dosage of the drug used, had one of the following characteristic:
A Suspected Unexpected Serious Adverse Reaction (SUSAR) is the term used to refer to an adverse event that occurs in a clinical trial subject, which is assessed as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. It is defined as an untoward and unintended response to a study drug, at any dose, which is not listed in the product information, and meets one of the above mentioned serious characteristics.
Generally AEs are collected after signing the informed consent form and could be related or unrelated to the study drug.
For any AE/SAE recorded during the study a causal relationship with the drug used will be assessed as follows:
World Health Organization (WHO) defines ADR as "a response to a drug which is noxious \& unintended and which occurs at doses normally used for prophylaxis diagnosis or therapy of a disease or for modification of a physiological function".
The difference between AE and ADR is that AE event does not imply causality but not for ADR, a causal rule is suspected.
An ADR unexpected is defined an ADR that for nature and severity is not listed in the product information (Reference Safety Information (RSI)/Investigator's Brochure (IB)).
Toxicity evaluation Urine culture is performed 3 days before each bladder instillation to check urine sterility (mandatory before the first course, optional before the following instillations). Treatment related adverse events are recorded by the patients on a diary.
Outcome analysis: adverse events are self-recorded by the patients after each instillation and classified by the investigator according to a classification grid considering account duration and intensity as proposed by Saint et al. Thus, toxicity is classified as systemic or local and class I (mild) up to class III (severe). The baseline symptoms are also assessed. Local toxicity included bacterial cystitis, BCG induced cystitis, frequency, macroscopic hematuria and "other". Bacterial cystitis is defined as the occurrence of culture proven (not BCG) bacterial cystitis. Irritative bladder symptoms with negative urine culture are classified as BCG induced (chemical) cystitis. "Other" local side effects include granulomatous prostatitis, epididymitis, ureteral obstruction and contracted bladder. Systemic side effects are classified as fever (≥39 °C), influenza like symptoms including general malaise and chills, BCG induced lung infection, liver toxicity, and BCG sepsis. Skin rash, arthralgia and arthritis are classified as possible allergic reactions. Based on the severity of adverse events experienced by the patient, one of the investigator, who is blind to the given therapy, decides whether the next instillation is to be done, postponed, deleted or whether the patient should receive specific anti-tuberculosis therapy. Dose reduction is not allowed in either group. Patients will also complete flow-volume charts for three days after BCG instillations and two questionaries to assess urinary symptoms and patient's perception of bladder pain as the chronic prostatitis symptoms index (NIH-CPSI) and the pelvic pain and urgency/frequency questionaire (PUF). The efficacy of both treatments is assessed at 3, 6,9,12 months with flexible cystoscopy, urinary cytology and bladder biopsy if needed.
STATISTYCAL ANALYSIS Using type I error, and a power of 2.5% and 81% respectively, and by proposing the hypothesis that Immucyst induced a recurrence in about 60% of cases (EORTC risk score 10) and its combination with mitomycin decreases this percent by 30%, it was calculated that 66 subjects per group were necessary to detect this difference using the adjusted chi-square method and Statistical Solution calculator. Student's T test was used for continuous variables. Two-sided p values were calculated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive Bacillus Calmette-Guérin induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG).
Patients received BCG treatment with the same protocol. Intervention will be a 40 mg mitomycin instillation the day before every single BCG instillation
Drug: Mitomycin
Patients receive BCG induction treatment according to the standard protocol (an instillation once a week for six weeks) with ImmuCyst (81 mg Connaught strain BCG) with a 40 mg mitomycin instillation the day before .
Also known as: Bacillus Calmette-Guerin
Recurrence rate
To evaluate the effect in term of recurrence rate of sequential combination therapy of Mitomycin and Bacillus Calmette-Guérin versus Bacillus Calmette-Guérin monotherapy in patients with High grade Non-Muscle Invasive Bladder Cancer.through cystoscopy every three months and Uro Tomography Computerized yearly
Time frame: 2 years
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
To evaluate the overall toxicity of sequential combination therapy of Mitomycin and Bacillus Calmette-Guérin versus Bacillus Calmette-Guérin monotherapy through CTCAE v4.0. Patients have to fill in International Prostate Symptoms Score, NIH-CPSI, PUF questionaries. Every three months patients will be visited and have a cystoscopy. We will hear about self-reported symptoms and we will measure body temperature
Time frame: 2 years
No study locations are listed for this record.
Start is estimated for Jan 2019; primary completion for Sep 2019, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitomycin
Azienda Ospedaliera "Sant'Andrea"